| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 04/16/2002 | US6372258 Methods of spray-drying a drug and a hydrophobic amino acid |
| 04/16/2002 | US6372250 Non-invasive gene targeting to the brain |
| 04/15/2002 | WO2002030514A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/15/2002 | CA2421622A1 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/11/2002 | WO2002029088A2 Highly expressible genes |
| 04/11/2002 | WO2002029061A2 G-protein coupled receptors |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002029010A2 Method for obtaining in vitro mammal islet cells and uses thereof |
| 04/11/2002 | WO2002028847A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/11/2002 | WO2002028837A1 Metabotropic glutamate receptor antagonists |
| 04/11/2002 | WO2002028820A1 Nitroso diphenylamine derivatives |
| 04/11/2002 | WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | WO2002028347A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 04/11/2002 | WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | WO2001092308A3 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 04/11/2002 | WO2001090070A3 Caspase inhibitors and uses thereof |
| 04/11/2002 | WO2001090069B1 Novel calcium receptor active molecules and method for preparing same |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001060372A3 Use of xanthine derivatives for preparing a medicine for preventing and treating osteoporosis |
| 04/11/2002 | WO2001032680A3 18-nor-steroids as selectively active estrogens |
| 04/11/2002 | WO2000036103A9 Cytokine receptor chain |
| 04/11/2002 | US20020042560 Gastrointestinal probe |
| 04/11/2002 | US20020042443 Estrogen agonist / antagonist metabolites |
| 04/11/2002 | US20020042435 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/11/2002 | US20020042434 Pharmaceutical composition |
| 04/11/2002 | US20020042415 Dipeptide derivatives |
| 04/11/2002 | US20020042376 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 04/11/2002 | US20020042359 Regulators of PPARdelta (beta) and their use in the treatment of obesity and insulin resistance |
| 04/11/2002 | CA2641575A1 Stabilization of solid thyroid drug formulations |
| 04/11/2002 | CA2641570A1 Stabilization of solid thyroid drug formulations |
| 04/11/2002 | CA2425269A1 G-protein coupled receptors |
| 04/11/2002 | CA2425152A1 Highly expressible genes |
| 04/11/2002 | CA2425126A1 Lipid metabolism enzymes |
| 04/11/2002 | CA2424684A1 Nitroso diphenylamine derivatives |
| 04/11/2002 | CA2424620A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | CA2424279A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/11/2002 | CA2424216A1 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | CA2421782A1 Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists |
| 04/10/2002 | EP1195178A1 Immunotrophic preparation for treating adenotonsillary hypertrophy |
| 04/10/2002 | EP1195166A2 Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension |
| 04/10/2002 | EP1195164A1 Remedies for drug-resistant hypercalcemia |
| 04/10/2002 | EP1194443A1 Cysteinyl protease inhibitors |
| 04/10/2002 | EP1194422A1 Biaryl compounds |
| 04/10/2002 | EP1194421A1 Selective npy (y5) antagonists |
| 04/10/2002 | EP1194409A1 Pyrazolidinol compounds |
| 04/10/2002 | EP1194167A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 04/10/2002 | EP1194155A1 Synergistic compositions containing lycopene and silymarin for treatment of liver disease |
| 04/10/2002 | EP0918774B9 Androgen receptor modulator compounds and methods |
| 04/10/2002 | EP0833642B1 Compressed dry-granulation desogestrel tablets |
| 04/10/2002 | CN1344326A Petroviral vectors comprising functional and non-functional splice donor and splce acceptor sites |
| 04/10/2002 | CN1344249A 酰胺衍生物 Amide derivatives |
| 04/10/2002 | CN1344163A Stabilized oral pharmaceutical compsn. contg. iodide and iodate and method |
| 04/10/2002 | CN1344155A Transnasal transport/immunisation with highly adaptable carriers |
| 04/09/2002 | US6369099 Method of locking 1 α-OH of vitamin D compounds in axial orientation |
| 04/09/2002 | US6369056 Agonists and antagonists of the progesterone receptor; contraceptives; 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydro -3-oxa-1,8-diaza-naphthalene-2-one and 6-chloro-4,4-dimethyl-1,4-dihydro-3-oxa-1,5-diaza-naphthalen-2-one |
| 04/09/2002 | US6369047 Androgenic steroid compounds and a method of making and using the same |
| 04/09/2002 | US6368816 11-beta-reductase inhibitor such as carbenoxolone to control 11-keto steroid conversion to 11-beta-hydroxysteroid; antidiabetic agents |
| 04/04/2002 | WO2002026935A2 TGF-β INHIBITORS AND METHODS |
| 04/04/2002 | WO2002026829A1 Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis |
| 04/04/2002 | WO2002026781A2 Ige receptor antagonists |
| 04/04/2002 | WO2002026763A1 19-NOR-17α-PREGNA-1,3,5 (10)-TRIEN-17β-OLS OF A 21,16α-LACTONE RING |
| 04/04/2002 | WO2002026759A2 17α FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS |
| 04/04/2002 | WO2002026727A2 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | WO2002026279A1 E-ptfe foil impregnated with an encapsulated bioactive substance |
| 04/04/2002 | WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| 04/04/2002 | WO2002026215A2 Thermogelling biodegradable aqueous polymer solution |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2001090137A3 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ONE |
| 04/04/2002 | WO2001089451A3 Protease inhibitors |
| 04/04/2002 | WO2001085784A3 POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001064227A3 Androgenic activity of eucommia ulmoides extracts |
| 04/04/2002 | WO2001050848A3 Clonal propagation of primate offspring by embryo splitting |
| 04/04/2002 | US20020039996 Pharmaceutical administration form for peptides, process for its preparation, and use |
| 04/04/2002 | US20020039736 Reacting aliphatic aminonitrile with water in presence of solid alumina catalyst to form lactam |
| 04/04/2002 | US20020039577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes |
| 04/04/2002 | DE10045380A1 Verfahren zur Kontrazeption und dessen Darreichungsform Method of contraception and its dosage form |
| 04/04/2002 | DE10043846A1 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen 17-methyl steroids, processes for their preparation and pharmaceutical compositions containing this compound |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | CA2423313A1 Methods of treating inflammatory and immune reactions and compositions therefor |
| 04/04/2002 | CA2422056A1 17.alpha. fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds |
| 04/04/2002 | CA2421851A1 Tgf-.beta. inhibitors and methods |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/03/2002 | EP1193261A1 New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/03/2002 | EP1192943A2 Use of growth hormone secretagogues in conjunction with physical exercise |
| 04/03/2002 | EP1192278A1 48 human secreted proteins |
| 04/03/2002 | EP1192266A2 Complement-resistant non-mammalian dna viruses and uses thereof |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192161A2 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands |
| 04/03/2002 | EP1192150A1 New pharmaceutically active compounds |
| 04/03/2002 | EP1191975A2 Improvement of t cell mediated immunity |
| 04/03/2002 | EP1191948A2 High dose radionuclide complexes for bone marrow suppression |
| 04/03/2002 | EP1191944A2 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP1191931A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| 04/03/2002 | EP1033990B1 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids |
| 04/03/2002 | EP1009393B1 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience |
| 04/03/2002 | EP0986574B1 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments. |